

17th September 2024

Contact:

silvia.humera@accessvetmed.eu

Tel. + 34 606848551

During the annual meeting of CEOs of the 27 member companies

Access VetMed shares in advance some of the conclusions from its European Veterinary Generics Market Study

- **60% of marketing authorization holders owning generic licenses** and around 50% of all veterinary medicine registrations now being generics.
- **Access VetMed members, hold 52%** of all veterinary generic registration in Europe.
- The 2024 edition of Access VetMed Generic Veterinary Medicines in Europe Study is expected to be published in the last quarter of the year. Its objectives are to provide an overview of the weight and prospects of generics in veterinary medicine.

[LINK TO PICTURE GALLERY](#)

Bucharest, 17th September 2024- Access VetMed, the voice of veterinary generic medicines in Europe, held its Annual General Managers Meeting on September 12 and 13 in Bucharest, Romania, with the support of **Farmavet** as the hosting company. The event brought together up to 60 CEOs and staff from associated companies.

“An opportunity for the exchange of ideas, opinions, and practices, as well as for the debate on the main challenges facing this sector”, said **Xavier Molins**, Access VetMed chair. Among the main topics covered were the progress with implementation of Regulation 2019/6 on veterinary medicines and the impact of UK's exit from the European Union (Brexit) in this business.

One of the most significant moments of the event was the presentation of the preliminary conclusions from the **Access VetMed European Generic Medicines Market Study 2024**, which is expected to be published during the last quarter of the year.

Marc Cayol, Study Market Task Force Lead, highlighted a key finding: "One of the most significant insights from the data is the substantial contribution of the Veterinary Generic Industry to the global market, accounting for over 35% of the EU's total revenue and employing around 30,000 out of 50,000 workers (60%)." Other important findings show that EU countries are home to manufacturers of veterinary generic products, with product registrations across all EU nations. Additionally, the industry is actively investing in product development, including for minor species, and in R&D to improve formulations and features, benefiting prescribers and users alike.

According to **Andreas Asamer**, CEO of VetViva and a board member of Access VetMed, "This study shows that generics have grown into a significant player in Europe. In fact, 60% of marketing authorization holders owning generic licenses and around 50% of all veterinary medicine registrations now being generics nowadays. As for Access VetMed members, we hold 52% of all generic registrations."

The study, the 2024 edition of which is set to be published in the last quarter of the year, aims to provide an overview of the importance and future prospects of generics in veterinary medicine. It is based on data from public databases, qualitative and quantitative surveys of its members, and analysis of the collected data.

A key focus of the study is the impact of Regulation 2019/6, which aims to reduce administrative burdens, improve the internal market, and increase the availability of veterinary medicinal products while ensuring the highest level of public and animal health, as well as environmental protection.

However, rather than achieving its goals, the new regulation is increasing costs, mainly due to new hires and investments companies in the sector have had to make to adapt to the new requirements. According to **Aafke Huizenga**, Associate Director of Dechra and leader of Access VetMed's Variations Working Group, who also participated as speaker at the meeting, "There is a need to establish metrics and indicators to evaluate how the implementation of the Regulation delivers as per its objectives, and how it impacts the generic and animal health business."

Additionally, **Xavier Molins**, Access VetMed chair, spoke about the impact of Brexit on the veterinary generic medicines sector in Europe. He stated, "The new UK Veterinary Medicines Regulations 2024, which came into force on May 17, 2024, is in many aspects aligned with EU Regulation 2019/6, but there are still some 'differences,' and the UK still acts as a sovereign regulator".

He concluded by announcing that Access VetMed, together with other industry stakeholders, participated very actively in the consultation process to ensure that any divergence with EU Regulation 2019/6 will not significantly impact the day-to-day operations and business of the Animal Health generic industry.”

About Access VetMed

Access VetMed was founded in 2002 as the European Group for Generic Veterinary Products (EGGVP) to serve as the voice of the generic veterinary medicines industry in Europe. Today, we represent **27 generic and added-value veterinary medicines companies** located in various European countries, including smaller markets. Together, our members have **a turnover of over 2,4 billion euros** and support **more than 8.600 direct jobs, holding 52% of all generic veterinary medicines marketing authorizations** in Europe.

We actively and constructively engage with EU regulators and other stakeholders to advocate for transparent, harmonized, pragmatic and balanced animal health regulation. Our primary objective is to increase ACCESS – availability, compliance, convenience, efficacy, safety, and savings – of veterinary medicines to veterinarians, farm, and companion animal owners in Europe.

More information: www.accessvetmed.eu

###